ACCUREXA, INC. (ACXA) and Other Medical Device Companies Add Value for Patients and Investors

NEW YORK, NY--(Marketwired - November 28, 2016) - Accurexa, Inc. (OTCQB: ACXA), a small-cap biotech focused on chemotherapy and immunology, is an up-and-coming leader in the neurological therapy space. Currently, Accurexa is working on the targeted delivery of such therapies, specifically the direct delivery of chemotherapeutics that effectively and safely cross the blood-brain barrier, www.accurexa.com.

According to Allied Market Research, the market opportunity for oncology treatments is forecast to reach $111.9 billion by 2020, achieving a compound annual growth rate of 7.1 percent. In 2015, the global cancer drugs market reached $78.24 billion, largely driven by increased demand for biological and targeted drug therapies for various cancers.

Leading the market are immunotherapy drugs, which offer a desirable risk-reward profile. The past few years have seen a tremendous boost in sentiment toward targeted cancer therapies due to their ability to protect healthy cells from toxic side effects common in other treatments.

The medical device market has many up and coming investment opportunities targeting a wide variety of health conditions and diseases. Consider Integra Lifesciences Holdings Corp. (NASDAQ: IART), a company which has a range of products targeting neurosurgery and implants, helping doctors deliver the best surgery by providing the right tools for each operation. With a market cap of $2.93 billion and 26 percent growth on share price, this company offers strong growth potential for investors.

Cardiovascular Systems (CSII) has developed heart implants and devices. With heart disease the leading cause of death worldwide, the potential market is tremendous. In 2012 alone, 17.5 million people died due to cardiovascular events. CSII has a range of products all designed to target coronary artery disease. By offering catheter delivery of stents, this company helps patients get rapid treatment with minimal recovery times. A market cap of $797.13 million gives investors plenty to look at when considering this company. CSII has realized gains of 65 percent, even with the uncertainty currently plaguing the market.